3 Publications

3.1 Papers

3.1.6 Chronological list

Section Contents | ref 1 | ref 2 | ref 3 | ref 4 | ref 5 | ref 6 | ref 7 | ref 8 | ref 9 | ref 10 | ref 11 | ref 12 | ref 13 | ref 14 | ref 15 | ref 16 | ref 17 | ref 18 | ref 19 | ref 20 | ref 21 | ref 22 | ref 23 | ref 24 | ref 25 | ref 26 | ref 27 | ref 28 | ref 29 | ref 30 | ref 31 | ref 32 | ref 33 | ref 34 | ref 35 | ref 36 | ref 37 | ref 38 | ref 39 | ref 40 | ref 41 | ref 42 | ref 43 | ref 44 | ref 45 | ref 46 | ref 47 | ref 48 | ref 49 | ref 50 | ref 51 | ref 52 | ref 53 | ref 54 | ref 55 | ref 56 | ref 57 | ref 58 | ref 59 | ref 60 | ref 61 | ref 62 | ref 63 | ref 64 | ref 65 | ref 66 | ref 67 | ref 68 | ref 69 | ref 70 | ref 71 | ref 72 | ref 73 | ref 74 | ref 75 | ref 76 | ref 77 | ref 78 | ref 79 | ref 80 | ref 81 | ref 82 | ref 83 | in press

3.1.6.48 Koonin, E.V., and Abagyan, R.A. (1997). TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nature Genetics, 16, 330-331

The TSG101 gene has been implicated in sporadic breast cancer. Knockout of the murine orthologue resulted in fibroblast transformation and ability to form tumours. The TSG101 protein contains a proline rich region and a predicted coiled cil domain, but no functional clues have been extracted from the sequence. We show that the N-terminal domain of TSG101 belongs to a group of apparently inactive homologoues of ubiquitin-conjugating enzymes (E2), which may be dominant negative regulators of E2 activity in cell-cycle control.